secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2023-11-29T23:59:59+00:00
Accession:  0001628280-23-040222
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead Pharma reports FY2023 net loss of $205M, pipeline advances
--------------------------------------------------------------------

- Revenue $240.7M vs $243.2M YoY; net loss $205.3M (EPS -$1.92) vs $176.1M (-$1.67).
- Cash and investments $403.6M, down from $482.3M; R&D spend up 19% to $353M.
- Plozasiran (APOC3) showed up to 90% APOC3 reduction in Phase 2 severe hypertriglyceridemia.
- Completed GLP tox for pulmonary candidates ARO-RAGE and ARO-MMP7; planning Phase 2.
- GSK acquired full rights to JNJ-3989 (ARO-HBV) from Janssen; Arrowhead retains no further obligations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000162828023040222/0001628280-23-040222-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000162828023040222/arwr-20231129.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-040222

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer